Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Human Resources Officer | February 11, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,650 |
Reported balance
After 2026-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 11,650 · Balance 11,650 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.47 · Expires 2036-02-10 | Direct | 17,500 |
Reported balance
After 2026-02-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-11 · Grant · Acquired 17,500 · Balance 17,500 F3: The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.
F3: The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2026 Filed Feb 13, 2026 22:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $98.47 | $0.00 |
DisclosureSEC source: 0001104659-26-015396 · tm266366-1_4seq1.xml · derivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2036-02-10 F3 · derivative.exercise_date: The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 22:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 11,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-015396 · tm266366-1_4seq1.xml · derivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 11,650 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009758 · tm264963-1_4seq1.xml · derivative · entry 6 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009758 · tm264963-1_4seq1.xml · derivative · entry 5 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,600 Underlying: Common Stock · 3,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009758 · tm264963-1_4seq1.xml · derivative · entry 4 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,650 Underlying: Common Stock · 2,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009758 · tm264963-1_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,343 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 1, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 1, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Tax withholdingCommon Stock | 4,731 | $108.99 | $515,631.69 |
DisclosureSEC source: 0001104659-26-009758 · tm264963-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,376 F2 · kind: These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 13,293 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-009758 · tm264963-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,350 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-25-121181 · tm2533512-1_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,375 Underlying: Common Stock · 3,350 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,350 | $111.00 | $371,850.00 |
DisclosureSEC source: 0001104659-25-121181 · tm2533512-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,814 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,350 | $27.35 | $91,622.50 |
DisclosureSEC source: 0001104659-25-121181 · tm2533512-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,350 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-25-115421 · tm2531966d1_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,725 Underlying: Common Stock · 3,350 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,350 | $105.00 | $351,750.00 |
DisclosureSEC source: 0001104659-25-115421 · tm2531966d1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,814 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,350 | $27.35 | $91,622.50 |
DisclosureSEC source: 0001104659-25-115421 · tm2531966d1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,515 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-25-110430 · tm2530920-1_4seq1.xml · derivative · entry 8 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,520 Underlying: Common Stock · 3,515 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,515 | $100.00 | $351,500.00 |
DisclosureSEC source: 0001104659-25-110430 · tm2530920-1_4seq1.xml · nonDerivative · entry 5 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,814 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,515 | $6.80 | $23,902.00 |
DisclosureSEC source: 0001104659-25-110430 · tm2530920-1_4seq1.xml · nonDerivative · entry 4 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,546 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-25-110430 · tm2530920-1_4seq1.xml · derivative · entry 7 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,035 Underlying: Common Stock · 10,546 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 8,805 | $0.00 Strike: $19.02 | $0.00 |
DisclosureSEC source: 0001104659-25-110430 · tm2530920-1_4seq1.xml · derivative · entry 6 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,257 Underlying: Common Stock · 8,805 shares Expires 2031-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 19,351 | $98.82 | $1,912,325.81 |
DisclosureSEC source: 0001104659-25-110430 · tm2530920-1_4seq1.xml · nonDerivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,814 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 10,546 | $6.80 | $71,712.80 |
DisclosureSEC source: 0001104659-25-110430 · tm2530920-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 8,805 | $19.02 | $167,471.10 |
DisclosureSEC source: 0001104659-25-110430 · tm2530920-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2025 Filed Jul 29, 2025 22:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,520 | $85.93 | $130,613.60 |
DisclosureSEC source: 0001104659-25-071849 · tm2522015-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,814 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| July 26, 2025 Filed Jul 29, 2025 22:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-071849 · tm2522015-1_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of July 26, 2022, July 26, 2023, July 26, 2024 and July 26, 2025. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of July 26, 2022, July 26, 2023, July 26, 2024 and July 26, 2025. The restricted stock units have no expiration date. Read SEC document |
| July 26, 2025 Filed Jul 29, 2025 22:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-071849 · tm2522015-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,025 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-25-067427 · tm2520691-1_4seq1.xml · derivative · entry 7 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,075 Underlying: Common Stock · 5,025 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,547 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-25-067427 · tm2520691-1_4seq1.xml · derivative · entry 6 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,581 Underlying: Common Stock · 10,547 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,516 | $80.00 | $281,280.00 |
DisclosureSEC source: 0001104659-25-067427 · tm2520691-1_4seq1.xml · nonDerivative · entry 5 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,209 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 7,831 | $76.69 | $600,564.87 |
DisclosureSEC source: 0001104659-25-067427 · tm2520691-1_4seq1.xml · nonDerivative · entry 4 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,725 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $76.17 to $76.75 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 4,225 | $75.55 | $319,217.34 |
DisclosureSEC source: 0001104659-25-067427 · tm2520691-1_4seq1.xml · nonDerivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,556 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $75.08 to $75.98 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 5,025 | $27.35 | $137,433.75 |
DisclosureSEC source: 0001104659-25-067427 · tm2520691-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 10,547 | $6.80 | $71,719.60 |
DisclosureSEC source: 0001104659-25-067427 · tm2520691-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,031 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-25-058188 · tm2517539-1_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,128 Underlying: Common Stock · 7,031 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 7,031 | $68.05 | $478,434.94 |
DisclosureSEC source: 0001104659-25-058188 · tm2517539-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,209 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $68.00 to $68.18 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 7,031 | $6.80 | $47,810.80 |
DisclosureSEC source: 0001104659-25-058188 · tm2517539-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2025 Filed May 1, 2025 20:53 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,031 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-25-043557 · tm2513769-2_4seq1.xml · derivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,159 Underlying: Common Stock · 7,031 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| April 29, 2025 Filed May 1, 2025 20:53 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 7,031 | $65.09 | $457,663.26 |
DisclosureSEC source: 0001104659-25-043557 · tm2513769-2_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,209 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65 to $65.42 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 29, 2025 Filed May 1, 2025 20:53 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 7,031 | $6.80 | $47,810.80 |
DisclosureSEC source: 0001104659-25-043557 · tm2513769-2_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 21:17 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,700 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-25-033821 · tm2512047-2_4seq1.xml · derivative · entry 8 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 6,700 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 21:17 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 14,060 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-25-033821 · tm2512047-2_4seq1.xml · derivative · entry 7 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,190 Underlying: Common Stock · 14,060 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 21:17 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 7,030 | $62.00 | $435,860.00 |
DisclosureSEC source: 0001104659-25-033821 · tm2512047-2_4seq1.xml · nonDerivative · entry 6 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,209 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 21:17 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 6,700 | $60.00 | $402,000.00 |
DisclosureSEC source: 0001104659-25-033821 · tm2512047-2_4seq1.xml · nonDerivative · entry 5 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,239 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 21:17 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 600 | $59.00 | $35,400.00 |
DisclosureSEC source: 0001104659-25-033821 · tm2512047-2_4seq1.xml · nonDerivative · entry 4 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,939 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 21:17 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 6,430 | $58.36 | $375,230.37 |
DisclosureSEC source: 0001104659-25-033821 · tm2512047-2_4seq1.xml · nonDerivative · entry 3 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,539 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $58.00 to $58.735 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 21:17 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 6,700 | $27.35 | $183,245.00 |
DisclosureSEC source: 0001104659-25-033821 · tm2512047-2_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 21:17 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 14,060 | $6.80 | $95,608.00 |
DisclosureSEC source: 0001104659-25-033821 · tm2512047-2_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 02:43 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 982 | $57.22 | $56,190.04 |
DisclosureSEC source: 0001104659-25-015317 · tm257103-1_4seq1.xml · nonDerivative · entry 2 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,209 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:43 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015317 · tm257103-1_4seq1.xml · derivative · entry 5 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,900 Underlying: Common Stock · 3,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:43 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-015317 · tm257103-1_4seq1.xml · nonDerivative · entry 1 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:43 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $56.69 | $0.00 |
DisclosureSEC source: 0001104659-25-015317 · tm257103-1_4seq1.xml · derivative · entry 4 Cramer Pamela J. · CIK 0001873517 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-02-13 F4 · derivative.exercise_date: The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.